Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
Note: If you attended this webinar on September 12, 2017 or October 3, 2017 and received CE credit (i.e. a pharmacist or pharmacy technician CE statement of credit with ACPE UAN 0221-0000-17-378-L05-P/T), you will not be eligible to receive CE credit for the home-study on-demand web activity.
With the implementation date of USP Chapter <800> fast approaching, pharmacies have little time left to ensure they become compliant with these newest regulations. This educational activity will help pharmacists and pharmacy technicians understand and prepare for these new standards. An overview of the risks of working with hazardous drugs and how ensuring compliance with USP <800> will mitigate these risks will be reviewed. This activity will also discuss strategies on how to implement and maintain compliance with USP <800>.
At the completion of this webinar, the participant will be able to:
Fred Massoomi, Pharm.D., FASHP
Senior Director of Health-system & Hospital Services
Andrew Szkiladz, PharmD, BCPS, BCOP
Regional Oncology Pharmacy Manager
Release Date: September 12, 2017
Expiration Date: October 31, 2018
ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-17-378-H05-P/T has been assigned to this home-study knowledge-based activity (initial release date September 12, 2017). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed in this activity. Dr. Massoomi has served
as a speaker for ICU Medical. Dr. Szkiladz has served as a speaker for ICU Medical.
Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
This activity is supported by an educational grant from ICU Medical.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.